Cullinan Therapeutics (CGEM) posts Q1 loss, advances autoimmune and cancer pipeline
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Cullinan Therapeutics reported first quarter 2026 results and highlighted key pipeline milestones in autoimmune disease and oncology. Cash, cash equivalents, investments and interest receivable were $393.3 million as of March 31, 2026, which the company expects will fund operations into 2029 under its current plan.
The company booked a net loss of $49.7 million, with research and development expenses of $42.1 million and general and administrative expenses of $11.6 million for the quarter. Cullinan’s partner-led NDA for zipalertinib in EGFR ex20ins NSCLC was accepted by the U.S. FDA, with a PDUFA target action date of February 27, 2027.
Positive
- None.
Negative
- None.
Insights
Strong cash runway supports an advancing autoimmune and oncology pipeline despite ongoing losses.
Cullinan Therapeutics ended Q1 2026 with cash, cash equivalents, investments and interest receivable of $393.3 million, and expects this to provide runway into 2029. Quarterly net loss was $49.7 million, reflecting R&D of $42.1 million and G&A of $11.6 million, similar to the prior year period.
Pipeline momentum is notable. The U.S. FDA accepted the zipalertinib NDA for relapsed EGFR ex20ins NSCLC with a PDUFA date of February 27, 2027, and Cullinan is eligible for up to $130 million in U.S. regulatory milestones plus a 50/50 U.S. profit share. Multiple data readouts are planned in 2026 for T cell engager programs CLN-978, velinotamig and CLN-049 across autoimmune diseases and AML/MDS.
Overall, the filing shows a company still loss-making but with substantial capital and several near- to medium-term clinical and regulatory catalysts. Actual outcomes will depend on forthcoming trial data and regulatory decisions described for 2026 and 2027.
8-K Event Classification
2 items: 2.02, 9.01
2 items
Item 2.02
Results of Operations and Financial Condition
Financial
Disclosure of earnings results, typically an earnings press release or preliminary financials.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Cash and investments: $393.3 million
Net loss: $49.7 million
R&D expenses: $42.1 million
+5 more
8 metrics
Cash and investments
$393.3 million
Cash, cash equivalents, short- and long-term investments, and interest receivable as of March 31, 2026
Net loss
$49.7 million
Net loss for the three months ended March 31, 2026
R&D expenses
$42.1 million
Research and development expenses in Q1 2026
G&A expenses
$11.6 million
General and administrative expenses in Q1 2026
Cash and investments prior period
$393,282 thousand
Cash, cash equivalents, investments, and interest receivable as of March 31, 2026 in thousands per balance sheet
Zipalertinib PDUFA date
February 27, 2027
U.S. FDA PDUFA target action date for zipalertinib NDA in EGFR ex20ins NSCLC
Zipalertinib regulatory milestones
$130 million
Total potential U.S. regulatory approval milestones ($30M 2L and up to $100M 1L)
Total stockholders’ equity
$366,172 thousand
Total stockholders’ equity as of March 31, 2026
Key Terms
T cell engager, PDUFA target action date, NDA, EGFR ex20ins NSCLC, +2 more
6 terms
T cell engager medical
"T cell engagers have the potential to transform outcomes for people living with autoimmune diseases and cancer"
A T cell engager is an engineered protein drug that physically links a patient’s T cell — the immune system’s attack cell — to a diseased cell so the T cell will recognize and kill it. For investors it matters because clinical trial results, manufacturing success and safety profiles determine whether the therapy becomes a widely adopted, high-value treatment or a costly failure; think of it like a matchmaker that must reliably bring soldiers to the right target without triggering friendly fire.
PDUFA target action date regulatory
"PDUFA target action date of February 27, 2027"
The PDUFA target action date is the deadline set by the U.S. Food and Drug Administration (FDA) by which it aims to decide whether to approve or reject a new drug application. This date helps investors gauge when a company’s new medication might reach the market, potentially influencing sales and revenue expectations. It acts as a key milestone signaling progress in the drug approval process.
NDA regulatory
"Zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA"
An NDA, or nondisclosure agreement, is a legal contract that keeps certain information private between parties. It’s like a promise not to share sensitive details, helping protect business ideas, strategies, or data from being leaked or used without permission. For investors, NDAs help ensure that confidential information remains secure, enabling trust and open communication during business discussions.
EGFR ex20ins NSCLC medical
"zipalertinib NDA for relapsed EGFR ex20ins NSCLC accepted by U.S. FDA"
EGFR exon 20 insertion (ex20ins) NSCLC is a specific form of non-small cell lung cancer driven by small insertion mutations in the exon 20 region of the EGFR gene; think of it as a tiny change in a cell’s instruction manual that makes lung cells multiply uncontrollably. It matters to investors because these tumors often don’t respond to standard EGFR drugs, creating urgent demand for new targeted treatments whose clinical trial results, approvals, and pricing can materially affect a company’s revenue and stock value.
measurable residual disease (MRD) medical
"Enrollment continues in a parallel Phase 1 study in patients with AML and measurable residual disease (MRD)"
Measurable residual disease (mrd) is the small number of cancer cells that remain in a patient after treatment and can be detected only with very sensitive laboratory tests. Like finding a few hidden weeds after you think a garden is cleared, MRD signals the risk that disease may return and is used to judge how well a therapy worked, guide follow-up treatment, and influence clinical trial results and regulatory decisions—factors that can affect a drug’s commercial value.
cash runway financial
"Cullinan expects its cash resources to provide runway into 2029 under its current operating plan"
Cash runway is the amount of time a company can continue operating using its available cash before needing additional funding or generating enough revenue. It’s like a countdown showing how long a business can keep running with its current funds. Knowing the cash runway helps investors assess the company's financial health and whether it has enough resources to reach its goals or needs to find more support soon.
Earnings Snapshot
Net loss: $49.7 million
Q1 2026
Net loss
$49.7 million
Research and development expenses
$42.1 million
General and administrative expenses
$11.6 million
Cash and investments
$393.3 million
FAQ
What were Cullinan Therapeutics (CGEM) first quarter 2026 financial results?
Cullinan reported a net loss of $49.7 million for Q1 2026. Research and development expenses were $42.1 million and general and administrative expenses were $11.6 million, both broadly in line with the same period in 2025.
How much cash does Cullinan Therapeutics (CGEM) have and what is its runway?
Cullinan held $393.3 million in cash, cash equivalents, short- and long-term investments, and interest receivable as of March 31, 2026. Management expects these resources to provide operating runway into 2029 under the current operating plan.
What is the status of Cullinan Therapeutics’ zipalertinib NDA for EGFR ex20ins NSCLC?
The U.S. FDA accepted an NDA for zipalertinib in relapsed EGFR ex20ins NSCLC, with a PDUFA target action date of February 27, 2027. Cullinan is eligible for U.S. regulatory milestones and a 50/50 U.S. profit share with partner Taiho.
What upcoming clinical data milestones did Cullinan Therapeutics (CGEM) highlight for 2026?
Cullinan plans multiple 2026 readouts, including initial CLN-978 data in SLE and RA at the EULAR 2026 Congress, additional RA multi-dose data in Q3 2026, initial Sjögren’s data in Q4 2026, and updated CLN-049 AML/MDS data in the second half of 2026.
What potential milestone payments can Cullinan Therapeutics receive from the zipalertinib collaboration?
Cullinan is eligible to receive $30 million upon U.S. regulatory approval in second-line EGFR ex20ins NSCLC and up to $100 million upon first-line U.S. regulatory approval. The collaboration also includes a 50/50 profit share in the United States.
How did Cullinan Therapeutics’ operating expenses change year over year in Q1 2026?
Research and development expenses were $42.1 million in Q1 2026 versus $41.5 million in Q1 2025, a modest increase. General and administrative expenses declined to $11.6 million from $13.5 million, slightly reducing overall operating expenses year over year.